TG-100-115   Click here for help

GtoPdb Ligand ID: 5715

Synonyms: TG 100-115 | TG 100115 | TG100-115
PDB Ligand
Compound class: Synthetic organic
Comment: TG-100-115 is an isozyme-selective inhibitor of phosphatidylinositol-3-kinase (PI3K). The discovery and synthesis of this compound is described in [2], where it is compound 6. It has subsequently been reported to inhibit the kinase activity of the TRPM7 ion channel, an action that suppresses breast cancer cell migration and invasion [3].
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species

TG-100-115 is commercially available from our sponsors

2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/). All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 6
Hydrogen bond donors 4
Rotatable bonds 2
Topological polar surface area 144.06
Molecular weight 346.12
XLogP 1.95
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

✖
Canonical SMILES Oc1cccc(c1)c1nc2nc(N)nc(c2nc1c1cccc(c1)O)N
Isomeric SMILES Oc1cccc(c1)c1nc2nc(N)nc(c2nc1c1cccc(c1)O)N
InChI InChI=1S/C18H14N6O2/c19-16-15-17(24-18(20)23-16)22-14(10-4-2-6-12(26)8-10)13(21-15)9-3-1-5-11(25)7-9/h1-8,25-26H,(H4,19,20,22,23,24)
InChI Key UJIAQDJKSXQLIT-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)
No information available.
Summary of Clinical Use Click here for help
TG-100-115 has been assessed in a single Phase 1/2 clinical trial (NCT00103350), to ascertain its safety and its ability to reduce heart muscle damage in patients having angioplasty following heart attack. There are no other clinical trials for this compound in the ClinicalTrials.gov register (Oct 2018).
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Ischemia is believed to trigger VEGF-mediated vascular leakage, and de-regualtion of fluid movement between blood vessels and the interstitium. The PI3K and Src signalling pathways are intimately involved in the regulation of the microvascular processes performed by endothelial cells. In heart attacks tissue is deprived of oxygen (ischemia) and further tissue damage occurs following reperfusion (ie return of blood flow). It is hypothesised that inhibition of the PI3K pathway could help to reduce this type of ischemia/ reperfusion injury [2].